---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Cost-effectiveness evidence"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Cost-effectiveness evidence. Topics: Summary: published economic evaluations, Lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel: U.S. health care cost-effectiveness model, Acquisition cost input of the lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel model, Cabazitaxel versus a second androgen receptor-targeted agent after docetaxel and an androgen receptor-targeted agent: U.S. payer cost model, and 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics/cost-effectiveness"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary: published economic evaluations

No cost-effectiveness analysis or budget impact model of rinzimetostat was identified. Published U.S. models address comparators and the combination partner. A partitioned survival model of lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel from a U.S. health care perspective (60-month horizon, 3% annual discount for costs, January 2025 dollars) estimated 0.86 versus 0.76 QALYs, mean total costs of $165,958 versus $129,700, and an ICER of $358,990 per QALY gained; results were most sensitive to the overall survival hazard ratio and the per-cycle costs of both treatments. Authors employed by Sanofi, the manufacturer of cabazitaxel, state that the model used the price of 177Lu-DOTATATE as a proxy for a per-cycle cost of $32,062. A U.S. payer cost model of third-line cabazitaxel versus a second androgen receptor-targeted agent over 18 months estimated $323,095 (17%) in avoided total costs, driven by the management of symptomatic skeletal events and end-of-life care; the CARD trial used cabazitaxel 25 mg/m2, while 20 mg/m2 is used in U.S. practice. A U.S. payer model of genomic test-directed olaparib after a new hormonal agent (2019 dollars) estimated an ICER of $116,903 per QALY in one scenario and cost savings in the other. For darolutamide, a U.S. payer budget impact model in nmCRPC for a 1-million-member plan over 5 years estimated a budget increase of $158,640 ($0.0132 PMPM) in year 1 and savings of $149,240 ($0.0124 PMPM) by year 5, and a U.S. hospitalization budget impact analysis of darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer reported a cumulative budget impact of -$9.71 per treated member per month over 5 years.

Source: [Gogebakan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13224915/); [Flannery et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724722/); [Morgans et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9284907/); [Su et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7870786/); [Appukkuttan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10394191/); [Morgans et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11365817/)

<a id="topic-4.1-2"></a>

### Lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel: U.S. health care cost-effectiveness model

> “In this study, we evaluated the impact of these benefits on the cost-effectiveness of 177Lu-PSMA-617 versus cabazitaxel from a U.S. health care perspective.”
> “A partitioned survival model was developed to estimate lifetime costs and health outcomes associated with 177Lu-PSMA-617 versus cabazitaxel over a 60-mo horizon.”
> “OS and PFS associated with177Lu-PSMA-617 were derived from a retrospective cohort, and relative treatment effects (hazard ratios [HRs]) from the TheraP trial were applied to generate outcomes for patients treated with cabazitaxel.”
> “The analysis was conducted over a lifetime horizon of 60 mo with a 1-mo cycle length on the basis that over 99% of patients in our model transitioned to a terminal state within this period.”
> “An annual discount of 3% for costs was applied in the analysis in accordance with recommendations from the Second U.S. Panel on Cost-Effectiveness in Health and Medicine (17).”
> “All costs were adjusted to January 2025 U.S. dollars using the medical care component of the Consumer Price Index (23).”
> “In the base case analysis, 177Lu-PSMA-617 was associated with an average of 0.86 QALYs, compared with 0.76 QALYs for cabazitaxel. The mean total costs were $165,958 for 177Lu-PSMA-617 and $129,700 for cabazitaxel, resulting in an incremental cost of $36,258 and an incremental QALY gain of 0.10. This corresponded to an ICER of $358,990/QALY gained, exceeding the highest U.S. WTP threshold of $200,000/QALY.”
> “Cost-effectiveness results were most sensitive to the OS HR, the per-cycle cost of 177Lu-PSMA-617, and the per-cycle cost of cabazitaxel.”
> “At WTP thresholds of $50,000/QALY, $100,000/QALY, and $200,000/QALY, the corresponding maximum cost per cycle that would make 177Lu-PSMA-617 cost-effective was $23,499, $24,885, and $27,656, respectively.”
> “Probabilistic analyses found that 177Lu-PSMA-617 was cost-effective in 19.7% of iterations at a WTP threshold of $200,000/QALY, 4.7% at $100,000/QALY, and 2.2% at $50,000/QALY.”

Source: [Gogebakan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13224915/)

<a id="topic-4.1-3"></a>

### Acquisition cost input of the lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel model

> “The authors note that direct U.S. cost data for 177Lu-PSMA-617 were not available and therefore used the price of 177Lu-DOTATATE as a proxy, citing a pan-Canadian Oncology Drug Review (pCODR) report.”
> “The base-case per-cycle cost for 177Lu-PSMA-617 was $32,062, with a sensitivity range of $25,649–$38,474, reflecting a 20% variation around the base case (i.e., 80%–120%), consistent with the underlying Advanced Accelerator Applications model.”
> “Although the directional conclusion is unlikely to change, the magnitude of difference is likely greater than reported.”
> “Kyle Flannery, Paul Cavanaugh, and Kevin Steele are employees of Sanofi, the manufacturer of Jevtana (cabazitaxel) injection, and may hold shares or options in the company.”

Source: [Flannery et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724722/)

<a id="topic-4.1-4"></a>

### Cabazitaxel versus a second androgen receptor-targeted agent after docetaxel and an androgen receptor-targeted agent: U.S. payer cost model

> “We aimed to estimate healthcare costs avoided with the use of cabazitaxel as a third-line (3 L) treatment versus a second ARTA from a US payer perspective.”
> “Given the short life expectancy for the target population (median OS of 11.0–13.6 months) [19], a time horizon of 18 months was used for the reference case analysis, and scenario analyses were conducted for time horizons of 6, 12, and 24 months.”
> “The economic analysis included the costs associated with the management of SSEs, AEs, and end-of-life care.”
> “Cabazitaxel, as compared with a second ARTA, was associated with 58 fewer hospitalization days and 2 fewer ICU days and was estimated to avoid $323,095 (€274,630, 17%) in total costs, driven by SSEs management and end-of-life care.”
> “The CARD trial evaluated the 25 mg/m2 dose of cabazitaxel, while 20 mg/m2 is routinely used in clinical practice in the US.”

Source: [Morgans et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9284907/)

<a id="topic-4.1-5"></a>

### Genomic test-directed olaparib after a new hormonal agent: U.S. payer cost-effectiveness model

> “We aimed to evaluate the cost-effectiveness of genomic test-directed olaparib on MCRPC from the US payer perspective.”
> “A mathematical model combining a decision tree and partitioned survival model was established to measure the clinical and economic outcomes of olaparib and standard care for men with MCRPC who had disease progression while receiving a new hormonal agent.”
> “Direct medical costs were considered from a United States payer perspective, which was reported in 2019 United States dollars.”
> “Olaparib yielded an additional 0.063 and 0.068 of quality-adjusted life year (QALY) with the augmented cost of $7,382 and saved the cost of $ 1,980 compared to standard care in scenario A and B, respectively, which yielded an ICER of $116,903/QALY and a cost-saving option.”

Source: [Su et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7870786/)

<a id="topic-4.1-6"></a>

### Darolutamide in nonmetastatic castration-resistant prostate cancer: U.S. payer budget impact model

> “A budget impact model was developed to evaluate darolutamide for nmCRPC for a hypothetical 1-million-member plan over a 5-year period.”
> “Costs (drug acquisition, drug administration, and treatment-related adverse events [AEs]) were estimated for 2 scenarios: with and without darolutamide treatment for nmCRPC.”
> “Market share estimates were derived from interviews with physicians treating men with nmCRPC.”
> “For a plan with 1 million lives, there were approximately 90 incident cases of nmCRPC (46 high risk) each year, with 332 (109 high risk) treatment-eligible cases by year 5.”
> “Given the utilization of other agents, introducing darolutamide along with other targeted therapies was predicted to increase the total budget by $158,640 ($0.0132 per member per month [PMPM]) in year 1, which decreased over time to a cost savings of $149,240 ($0.0124 PMPM) by year 5.”

Source: [Appukkuttan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10394191/)

<a id="topic-4.1-7"></a>

### Darolutamide with docetaxel in metastatic hormone-sensitive prostate cancer: U.S. hospitalization budget impact analysis

> “Based on these estimates, a budget impact analysis evaluated the hospitalization costs (including ICU admissions) and standalone ICU hospitalization costs for the totality of the US population over a 5-year time horizon.”
> “The budget impact per treated member per month represents a cost-neutral option after Year 5 with a cumulative budget impact of -$9.71.”

Source: [Morgans et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11365817/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
